• Personalis highlighted clinical data already presented at ASCO 2026 on its NeXT Personal MRD blood test across multiple solid tumors.
• In a prospective colorectal cancer study, the test identified recurrence earlier than standard imaging, supporting use in post-surgery surveillance decisions.
• A lung cancer analysis showed the assay detected very low-level residual disease that correlated with higher relapse risk, pointing to earlier intervention opportunities.
• Additional ASCO presentations in ovarian, endometrial, and melanoma indicated ctDNA detection or clearance aligned with progression risk, supporting broader clinical adoption.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Personalis Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202606020600BIZWIRE_USPR_____20260602_BW445979) on June 02, 2026, and is solely responsible for the information contained therein.